• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Juventas Therapeutics launches clinical trial for stem cell factor in heart failure

Juventas Therapeutics launches clinical trial for stem cell factor in heart failure

April 6, 2010 By MedCity News

MedCity News logo

By Mary Vanac

Clinical-stage regenerative medicine company Juventas Therapeutics Inc. — a Cleveland Clinic spin-out initially named AcelleRX Therapeutics Inc. — started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its leading stem cell factor for treating heart failure.

In preclinical studies of heart failure in pigs, JVS-100, as the factor is known, significantly increased cardiac function by promoting cell survival and increasing blood vessel formation in damaged hearts. JVS-100 works by encoding Stromal Cell-derived Factor-1, a growth factor that in adults recruits stem cells from the bone marrow to create new blood vessels. The JVS-100-treated pigs showed significant improvements in cardiac function, including reductions in left ventricular end systolic volume, according to a press release.

Dr. Douglas Losordo, director of the Feinberg Cardiovascular Research Institute at Northwestern University, is the principal investigator for the 16-person study. Also investigators on the study: Dr. Farrell Mendelsohn, a cardiologist at Baptist Medical Center-Princeton in Birmingham, Ala., director of the Center for Therapeutic Angiogenesis Interventional & Regenerative Cardiovascular Medicine; and Dr. Warren Sherman, an interventional cardiologist who directs Stem Cell Research and Regenerative Medicine for the Center for Interventional Vascular Therapies at Columbia University Medical Center.

“Juventas is excited to have initiated this Phase 1 heart failure trial and honored to be working with a top-tier group of interventional cardiologists,” Juventas president and CEO Rahul Aras said. “The trial is an important milestone and represents the first of several clinical opportunities for our company.”

Juventas was formed in 2007 to develop and commercialize the stromal cell-derived factor research of Dr. Marc Penn, a Cleveland Clinic cardiologist who also is senior medical director for the Clinic’s emerging businesses unit. Penn is chief scientific officer for Juventas.

“SDF-1 was discovered by Marc as a homing factor. It serves as a beacon for circulating stem cells,” Aras said. “We’ve gone on to show that it works through multiple mechanisms,” including preventing cells in damaged tissue from dying.

Coupling that mechanism with the new blood vessel-forming ability of stem cells creates a two-step process: New blood vessels are created and existing cells don’t die, Aras said.

“If you look at that from a competitor’s perspective, it has the potential to simplify what a lot of regenerative medicine companies are working on, through the extraction and redelivery of cells, by optimizing our own stem cells,” he said.

Since 2007, “we’ve transitioned the technology from a preclinical concept to the first clinical trial,” he said. “So we’re on target to be able to complete this trial by the end of the year. That will be a big step for the company.”

What’s next?

“We’ve led with heart failure because that’s where our preliminary data was and it’s a great clinical opportunity,” Aras said. “We also have strong data in the area of peripheral vascular disease and cosmetic wound healing.”

The factor can increase blood flow for patients who have PVD and accelerate wound closure and prevent scarring for patients who have had cosmetic surgery. “So we’re looking to move both those toward clinic in the near future,” Aras said.

Juventas has closed on about $7.7 million in venture funding since its start, he said. In July 2007, the company raised $1.5 million from North Coast Angel Fund and venture developer JumpStart Inc., both in Cleveland, as well as from Blue Chip Venture Co. of Cincinnati and from individual investors. The firm raised another $6.9 million from a group of venture capital firms led by Triathlon Medical Ventures in Cincinnati during its Series A fundraising round in October 2008.

Juventas also received Ohio Third Frontier grants worth $2 million from the Cleveland Clinic-led Global Cardiovascular Innovation Center to further its heart failure platform and from the Center for Stem Cell and Regenerative Medicine in Cleveland to help further its peripheral vascular disease platform, Aras said.

“We have four full-time employees, two part-time employees. We’re still relatively small. As our clinical opportunities expand, so will the company,” he said.

“We have rights to a pipeline of factors that were discovered by [Penn],” Aras said. “JVS-100 is the first in a line of downstream opportunities that exist. With the capital we have and what we’re focused on right now, we are looking to drive JVS-100 forward, but we do have other factors that we’ll look to commercialize as the company matures. ”

Other upcoming milestones?

“We’re engaging with the Food & Drug Administration on future clinical trials in the area of peripheral vascular disease,” he said. “The big milestone for us is the completion of this Phase 1 clinical trial. But we are acting aggressively to further our other clinical platforms as well.”

Filed Under: Biotech, Business/Financial News, News Well, Stem Cells Tagged With: Juventas Therapeutics Inc.

In case you missed it

  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar
  • Masimo beats Street in Q2 as healthcare business catches up
  • Senseonics stock is up as it sticks by revenue guidance
  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit

RSS From Medical Design & Outsourcing

  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy